Semaglutide
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. After the March 2026 patent expiry in India, eight CDSCO-approved manufacturers launched generic versions, dramatically reducing costs. How it works Semaglutide mimics the action of GLP-1, a naturally occurring hormone released after eating. It slows gastric emptying, increases insulin […]